H.C. Wainwright maintained a positive stance on Arcturus Therapeutics (NASDAQ:ARCT) shares, reiterating a Buy rating and a price target of $63. Currently trading at $16.97, the stock has significant ...
While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback